Partnership to improve heart disease therapy
BIOTRONIK, a global producer of cardio- and endovascular medical products, has announced a strategic partnership with GenesisCare, the largest group of private practice cardiologists in Australia, to enhance outcomes for Australian cardiac patients.
Over the course of three years the partners will initiate interdisciplinary research projects focusing on better data sharing, care pathways and integration, as well as tracking outcomes. BIOTRONIK will contribute its vast technological knowledge to the partnership, while GenesisCare has established systems to monitor and measure patient outcomes.
“With the necessary technology and know-how, we aim to improve patient outcomes with more responsive, personalised and appropriate care,” said Dr Stephen Worthley, Executive Manager at GenesisCare. “This could lead to fewer adverse events, earlier detection of preventable problems and reduced need for hospitalisation.”
Cardiac patients can benefit from this new approach in terms of fewer hospital visits and complications, and lower mortality. This will ultimately translate into lower therapy costs, benefiting patients and health insurers.
“Our partnership aims to overcome obstacles we face when acting alone,” said Jan Ewert, Managing Director of BIOTRONIK Australia and New Zealand. “We look forward to collaborating with GenesisCare to work towards a common goal: redefining how patients receive the best possible care.”
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
